ADMA Biologics Inc (NASDAQ:ADMA) Stock Has Consensus Target Price of $18.67 According to Brokerages

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $18.67.

A number of equities research analysts have weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Mizuho dropped their price target on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Finally, Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd.

Institutional Trading of ADMA Biologics

Several hedge funds have recently modified their holdings of the stock. Western Wealth Management LLC acquired a new stake in ADMA Biologics in the first quarter valued at approximately $31,000. Integrated Wealth Concepts LLC bought a new stake in shares of ADMA Biologics during the second quarter valued at approximately $42,000. Quantbot Technologies LP acquired a new position in shares of ADMA Biologics during the second quarter worth approximately $51,000. Nykredit A S acquired a new position in shares of ADMA Biologics during the second quarter worth approximately $59,000. Finally, GAMMA Investing LLC lifted its holdings in shares of ADMA Biologics by 110.8% in the 3rd quarter. GAMMA Investing LLC now owns 6,119 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 3,216 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock opened at $10.36 on Monday. The business has a 50-day moving average price of $9.59 and a two-hundred day moving average price of $9.21. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $20.46. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The company has a market cap of $2.32 billion, a P/E ratio of 14.80 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%. The company had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same period in the previous year, the business earned $0.14 EPS. The firm’s revenue was up 2.0% compared to the same quarter last year. As a group, analysts anticipate that ADMA Biologics will post 0.78 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a commercial biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for people with compromised immune systems. The company’s operations include collecting human source plasma, developing therapies from donated plasma and producing specialty immunoglobulin products.

ADMA’s commercial portfolio includes BIVIGAM, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency, and ASCENIV, an intravenous immune globulin product for patients with primary immunodeficiency diseases.